| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.8M | — | +7524.2% |
| R&D Expense | $446K | — | +102.0% |
| SG&A Expense | $3.9M | — | +227.4% |
| Operating Income | -$2.5M | — | -83.0% |
| Net Income | -$2.2M | — | -82.3% |
| EPS (Basic) | -$0.25 | — | -47.1% |
| EPS (Diluted) | -$0.25 | — | -47.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.5M | +80.1% | — |
| Accounts Receivable | $80K | +5.6% | +1552.6% |
| Current Assets | $12.2M | -3.5% | -19.8% |
| Total Assets | $15.8M | +17.9% | -1.8% |
| Current Liabilities | $569K | -16.4% | +13.7% |
| Total Liabilities | $569K | -16.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.5M | — | -92.2% |
| Investing Cash Flow | -$2.1M | — | +79.6% |
| Financing Cash Flow | $5.3M | — | — |
| +13.7% |
| Stockholders' Equity | $15.9M | +21.4% | +1.9% |